| (Values in U.S. Thousands) | Mar, 2019 | Dec, 2018 | Sep, 2018 | Jun, 2018 | Mar, 2018 |
| Sales | 6,190 | 8,100 | 9,440 | 15,620 | 3,400 |
| Sales Growth | -23.58% | -14.19% | -39.56% | +359.41% | -26.57% |
| Net Income | -21,170 | -78,870 | -21,790 | -25,010 | -25,060 |
| Net Income Growth | +73.16% | -261.96% | +12.87% | +0.20% | +17.43% |
Prometic Life Scienc (PFSCD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
ProMetic Life Sciences Inc. is a biopharmaceutical company. The company is involved in bioseparations, plasma-derived therapeutics and small-molecule drug development. Its operating segment consists of Therapeutics and Protein Technology. Therapeutics segment products include PBI-4050 for treatment of fibrosis with chronic kidney diseases, certain cancers and side effects associated with chemotherapy; PBI-4419, an anti-fibrotic and anti-inflammatory compound for kidney injury and chronic kidney diseases and PBI-1402 for the treatment of anemia indications. Protein Technology segment provides plasma protein purification system, bioseparation products and prion capture/pathogen removal technology platform. ProMetic Life Sciences Inc. is headquartered in Laval, Canada.